Twist Bioscience (TWST) Operating Leases (2019 - 2026)

Twist Bioscience has disclosed Operating Leases across 8 years of filings, most recently posting $85.4 million for Q1 2026.

• In Q1 2026, Operating Leases rose 31.22% year-over-year to $85.4 million; the TTM figure through Mar 2026 stood at $85.4 million (up 31.22% YoY), while the FY2025 annual figure was $61.8 million, down 12.06% from the prior year.
• Operating Leases steadied at $85.4 million in Q1 2026, from $85.8 million in the prior quarter.
• Over the last five years, Operating Leases for TWST reached as high as $94.0 million in Q4 2022 and fell as low as $61.8 million in Q3 2025.
• The 5-year median for Operating Leases is $79.2 million (2023), against an average of $78.6 million.
• Annual changes were most pronounced in 2022 — Operating Leases soared 194.44% — and 2025, when it decreased 28.14%.
• A 5-year view of Operating Leases shows it stood at $94.0 million in 2022, then retreated by 2.23% to $91.9 million in 2023, then fell by 26.44% to $67.6 million in 2024, then gained by 26.96% to $85.8 million in 2025, then decreased by 0.48% to $85.4 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $85.4 million, $85.8 million, and $61.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.